Keeping track of new clinical trial opportunities across the United States can be a challenge, especially with many clinical trials actively enrolling patients. This report summarizes studies that have recently opened or started recruiting for adult and pediatric patients with a primary brain tumor between July 1, 2025 and June 10, 2026 (since our last update). Individuals are encouraged to follow the hyperlinks for each study to learn more and contact the responsible party for enrollment.
For a comprehensive list of ALL open brain tumor clinical trials, visit the NBTS Clinical Trial Finder, where you can search for potential opportunities for enrollment based on criteria specific to you.
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
This phase IIb trial tests an investigational ultrasound device (LIDU) combined with the drug 5-ALA, added to standard temozolomide, in patients with glioblastoma following surgery and chemoradiation.
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma (ADePT)
This phase I/II study evaluates the safety and efficacy of TGX-007, a gene therapy that delivers two payloads to kill tumor cells and activate an anti-tumor immune response, in patients with newly diagnosed or recurrent glioblastoma.
PH Sensitive MRI Based Resections of Glioblastoma
This phase I study tests whether a pH-sensitive MRI technique (amine CEST-EPI) can identify infiltrating tumor cells in patients with glioblastoma that is not visible on standard MRI, and whether using it to guide surgery to remove these additional areas is safe.
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
This trial evaluates whether a combination of three advanced MRI techniques (CEST MRI, DR-CSI, and ferumoxytol-enhanced MRI) can serve as non-invasive methods for assessing the tumor immune microenvironment in patients with glioblastoma, which may help explain why some tumors resist treatment.
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
This phase I study evaluates the safety and feasibility of laser interstitial thermal therapy (LITT) followed by lomustine (CCNU) in adults with recurrent glioblastoma.
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
This window-of-opportunity study tests whether adding azeliragon, a RAGE inhibitor, to radiation therapy and temozolomide can reduce immune-suppressive cells and restore immune activity in patients with newly diagnosed glioblastoma.
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care (BRIDGES)
This phase III trial compares standard chemoradiation to standard chemoradiation plus GammaTile (a radiation source implanted at the time of surgery) in patients with newly diagnosed glioblastoma, with the goal of beginning radiation immediately after tumor removal.
Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma
This early phase I trial tests the safety, best dose, and effectiveness of sonodynamic therapy, which combines a drug (SONALA-001 or 5-ALA HCL) with MRI-guided focused ultrasound to kill tumor cells, in patients with progressive or recurrent glioblastoma.
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
This phase II study tests the safety and effectiveness of adding the investigational drug ruxolitinib to standard radiation therapy and temozolomide in patients with newly diagnosed glioblastoma, compared to standard treatment alone.
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
This phase I study tests GPC3-CAR T-cells engineered with IL15 (GO-CART T cells), a treatment combining antibodies and immune T-cells, in patients with recurrent GPC3-positive glioblastoma.
BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors
This phase 0/II trial evaluates the pharmacokinetics, pharmacodynamics, safety, and efficacy of BGB-58067 in patients with newly diagnosed glioblastoma whose tumors have MTAP deletions and are scheduled for surgical resection.
Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma (BATs FUS)
This phase I study tests whether combining low-intensity focused ultrasound (to open the blood-brain barrier) with EGFR-targeted immune cell therapy (EGFR-BATs) is safe and feasible in patients with newly diagnosed MGMT-unmethylated, IDH wild-type glioblastoma.
A Phase I Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
This phase I dose-escalation study evaluates the safety, tolerability, and preliminary activity of the oral drug GLIX1 in adults with high-grade diffuse glioma that has progressed or recurred after prior therapy.
A Phase I/II Study of the Safety and Tolerability of MT-125 in GBM Patients (STAR-GBM)
This phase I/II study determines the recommended dose and safety of the investigational treatment, MT-125, given in combination with radiotherapy, in patients with newly diagnosed IDH wild-type, MGMT-unmethylated glioblastoma.
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
This phase Ib study evaluates different dosing approaches for CART-EGFR-IL13Ra2 cells and further characterizes their safety, feasibility, and preliminary efficacy in patients with EGFR-amplified glioblastoma that has recurred following prior radiotherapy.
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (GIANT)
This phase II trial investigates the feasibility, safety, and biological activity of nivolumab, with or without the drug, relatlimab, given before and after surgery in patients with IDH wild-type, newly diagnosed glioblastoma.
A Phase II and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
This phase II study evaluates whether sitagliptin, a drug FDA-approved for diabetes, can improve the immune response against the tumor by targeting immune-suppressing cells (MDSCs) in patients with progressive grade 4 glioma.
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial (ERAS801-SARG)
This phase Ib trial tests the safety and side effects of ERAS-801, an EGFR inhibitor that can penetrate the central nervous system, in patients with resectable, progressive, or recurrent IDH wild-type, EGFR-amplified or -mutated grade 4 glioblastoma or astrocytoma.
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
This study evaluates an intratumoral diffusing alpha-emitter radiation device (DaRT) for the treatment of patients with recurrent glioblastoma.
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
This phase II study tests whether combining silevertinib with temozolomide after surgery and radiotherapy treats patients with newly diagnosed glioblastoma (with unmethylated MGMT and EGFRvIII) better than temozolomide alone.
A Phase 0/I Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
This phase 0/I trial evaluates risvutatug rezetecan (GSK5764227), a B7-H3-targeted antibody-drug conjugate, in patients with recurrent WHO grade 4 glioma and patients with brain metastases.
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
This first-in-cancer-type phase I trial tests FT536, an investigational cell therapy administered directly into the tumor, in adults with recurrent WHO grade 4 astrocytoma undergoing repeat surgery.
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
This phase II trial compares GI-102 alone and in combination with pembrolizumab, given before surgery, in patients with recurrent or progressive IDH wild-type glioblastoma or IDH-mutated grade 4 astrocytoma. GI-102 is a bispecific fusion protein that may stimulate the immune system against the tumor.
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
This early phase I study evaluates the response and safety of lorlatinib in children with newly diagnosed high-grade glioma that has an ALK or ROS1 fusion, given with chemotherapy or after radiation therapy.
Precision Radiotherapy Enabled by Molecular MRI
This study evaluates whether a novel molecular MRI technique called amide proton transfer (APT) imaging can help identify the most aggressive areas of a brain tumor for targeted radiotherapy.
A Study of 177Lu-PSMA-617 in People With Gliomas
This phase I study evaluates whether the radiopharmaceutical therapy 177Lu-PSMA-617 is a safe treatment for people with IDH wild-type glioma.
RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) (PNOC020 rMB)
This phase I study aims to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose, of RNA-lipid particle (RNA-LP) vaccines in pediatric patients with recurrent or progressive medulloblastoma.
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT)
This phase I/II study examines the safety of adding tarlatamab, a bispecific T-cell engager targeting DLL3, to standard radiation therapy in patients with DLL3-expressing tumors, including those with cranial sites of disease.
ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower-Grade Gliomas
This phase I trial tests a peptide vaccine (PEPIDH1M) combined with vorasidenib, a drug that blocks mutant IDH1 and IDH2 enzymes, in adults with recurrent IDH1-mutant lower-grade glioma.
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
This phase I/II trial tests the investigational oral drug AMXT 1501 combined with eflornithine (DFMO) in children and young adults with several cancers, including DIPG and other CNS tumors, to find a recommended dose and assess safety and activity.
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
This phase I/II study tests a stem-cell transplant depleted of certain immune cells (αβ T cells and B cells) combined with zoledronic acid in children and young adults with relapsed or refractory solid tumors, to evaluate safety and whether it improves survival.
Digoxin Medulloblastoma Study
This phase II trial evaluates digoxin for treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High-Grade Gliomas
This phase II study evaluates the safety and effectiveness of ACT001 in patients with diffuse intrinsic pontine glioma (DIPG) and H3 K27-altered high-grade glioma.
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
This trial tests HOBSCOTCH-CA, a home-based program of one-on-one virtual cognitive coaching, to improve quality of life and cognitive function in brain tumor and brain cancer survivors, and to reduce burden on their caregivers.
A Phase 0/I Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies
This phase 0/I study tests the drug SGT-53 together with radiation and the immunotherapy drug nivolumab in children with recurrent, progressive, or refractory central nervous system tumors, to find a safe dose and assess side effects.
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
This phase I study evaluates the safety and effects of M032, an engineered herpes virus given directly into the tumor, in children and adults with newly diagnosed diffuse midline glioma who have completed standard radiation therapy.
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
This phase I study tests GPC2-targeted CAR T-cell therapy, delivered into the fluid-filled spaces of the brain, in children and young adults with relapsed or refractory medulloblastoma and other eligible CNS embryonal tumors.
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
This phase II trial studies whether reducing or stopping the drugs dabrafenib and trametinib—after 12–24 months of treatment—works well in patients with low-grade glioma carrying a BRAF V600 mutation, to help determine the best dosing strategy.
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
This phase I/II study tests the safety, best dose, and effectiveness of RYZ101, a radioactive drug that targets somatostatin receptors on tumor cells, in patients with progressive or recurrent intracranial meningioma.
Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma
This phase II study evaluates the effects and efficacy of metformin in children and young adults with recurrent or progressive posterior fossa group A (PFA) ependymoma.
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
This phase I study tests whether the investigational drug LMP744 can kill tumor cells in adults with glioblastoma that has returned after treatment.
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
This phase II study evaluates the efficacy and safety of the drug zanzalintinib in patients with recurrent or progressive meningioma that has not responded to standard therapies.
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
This study uses a PET imaging tracer ([C-11]-CS1P1) to measure inflammation in adults with primary or secondary central nervous system cancers, examining how imaging patterns relate to MRI findings, treatment, and outcomes.
Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma
This study evaluates how well laser interstitial thermal therapy (LITT) works in treating recurrent or progressive low-grade glioma in pediatric, adolescent, and young adult patients.
